Page last updated: 2024-12-08

mt 0703

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MT 0703: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	163788
MeSH ID	M0175114

Synonyms (8)

Synonym
mt 0703
pyridinium, 4-(((7-(((2-amino-4-thiazolyl)(((1,4-dihydro-1,5-dihydroxy-1,5-dihydroxy-4-oxo-2-pyridinyl)carbonyl)amino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)thio)-1-(2-hydroxyethyl)-, hydroxide, inner salt, (6r-(6alph
pyridinium, 4-(((7-(((2-amino-4-thiazolyl)(((1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)carbonyl)amino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)thio)-1-(2-hydroxyethyl)-, hydroxide, inner salt, (6r-(6-alpha,7-beta))-
antibiotic mt 0703
mt0703
108353-14-6
(6s,7s)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-[(1,5-dihydroxy-4-oxopyridine-2-carbonyl)amino]acetyl]amino]-3-[[1-(2-hydroxyethyl)pyridin-1-ium-4-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
pyridinium,4-[[[7-[[(2-amino-4-thiazolyl)[[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)carbonyl]amino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]thio]-1-(2-hydroxyethyl)-,inner salt, [6r-(6a,7b)]- (9ci)

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (50.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (50.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.38 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.32 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (33.33%)	6.00%
Case Studies	2 (33.33%)	4.05%
Observational	0 (0.00%)	0.25%
Other	2 (33.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
aztreonam Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.. aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.	1.97	1
cefoperazone Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.	1.97	1	cephalosporin	antibacterial drug
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	4.87	6	cephalosporin	fungal metabolite

Condition	Relationship Strength	Studies
Left Ventricular Dysfunction [description not available]	2.15	1
Ebstein Anomaly A congenital heart defect characterized by downward or apical displacement of the TRICUSPID VALVE, usually with the septal and posterior leaflets being attached to the wall of the RIGHT VENTRICLE. It is characterized by a huge RIGHT ATRIUM and a small and less effective right ventricle.	2.15	1
Ventricular Dysfunction, Left A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.	2.15	1
Incisional Hernia Protrusion of tissue at or near the site of an incision from a previous surgery.	3.04	1
Ventral Hernia [description not available]	3.04	1
Hernia, Ventral A hernia caused by weakness of the anterior ABDOMINAL WALL due to midline defects, previous incisions, or increased intra-abdominal pressure. Ventral hernias include UMBILICAL HERNIA, incisional, epigastric, and spigelian hernias.	3.04	1
Abdominal Aortic Aneurysm [description not available]	2.99	1
Aneurysm, Bacterial [description not available]	2.99	1
Bladder Cancer [description not available]	2.99	1
Fistula Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body.	2.99	1
Koch's Disease [description not available]	2.99	1
Cholecystoduodenal Fistula [description not available]	2.99	1
Duodenal Diseases Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL).	2.99	1
Aortic Diseases Pathological processes involving any part of the AORTA.	2.99	1
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.99	1
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	2.99	1
Aortic Aneurysm, Abdominal An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.	2.99	1
E coli Infections [description not available]	2.38	2
Infections, Klebsiella [description not available]	1.97	1
Infections, Pseudomonas [description not available]	2.38	2
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	2.38	2
Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA.	1.97	1
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	2.38	2

chemdatabank.com